Digital Biomarkers and Therapeutics - How will they look in 2024 or 2035? (Session @ HRX 2023)-Digital Biomarkers and Therapeutics- How will they look in 2025 or 2035?

Video Transcription

Video Summary

The discussion focused on the intersection of digital health, artificial intelligence, and cardiometabolic diseases, featuring experts in the field such as Abhinav Sharma, Jean-Philippe Coudert, Dan, Liz, and Murad. They highlighted the importance of utilizing digital tools for screening, identification, and stratification of chronic diseases like type 2 diabetes and heart failure. The panel addressed the significance of scalability, workflow optimization, data integration, and regulatory considerations in the future of healthcare technology.<br /><br />Key points included the need for impactful clinical trials to demonstrate outcomes, the importance of partnerships between healthcare, industry, and payers to drive innovation, and the challenge of integrating novel technologies into existing clinical workflows. Discussions touched on leveraging sensors, data aggregation, and patient engagement to improve quality of life and streamline healthcare delivery.<br /><br />The panelists also addressed the potential of digital biomarkers to reflect patient quality of life, the importance of focusing on workflow optimizations for successful implementation, and the role of patients in driving data-driven decision-making. They shared insights on future trends, including the widespread adoption of non-invasive technologies, patient-centric care models, and the integration of data integrative centers in healthcare by the year 2030.

Keywords

digital health

artificial intelligence

cardiometabolic diseases

chronic diseases

patient engagement

healthcare technology

sensors

data integration

2030